IDO1 and cancer: Compelling evidence from preclinical and clinical studies substantiates that the STING agonist therapy–induced immune responses are evaded by several types of tumors via various immune-inhibitory molecules, with the cancer cells also exploiting the IDO1 pathway to avoid immunotherapy-mediated destruction (18–20).